Vetoquinol SA (EPA:VETO)

Market Cap	1.03B +32.3%
Revenue (ttm)	532.39M -0.9%
Net Income	59.96M +27.2%
EPS	5.10 +27.9%
Shares Out	11.80M
PE Ratio	17.05
Forward PE	16.11
Dividend	0.89 (1.02%)
Ex-Dividend Date	Jun 4, 2025

Volume	1,504
Average Volume	3,397
Open	87.40
Previous Close	86.90
Day's Range	85.90 - 88.50
52-Week Range	68.10 - 88.50
Beta	1.02
RSI	65.44
Earnings Date	Mar 27, 2026

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,497
• Stock Exchange: Euronext Paris
• Ticker Symbol: VETO

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.